NewAmsterdam Pharma (NAMS) Company announced the commencement of an underwritten public offering of $300M of the company’s ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. Jefferies, Goldman Sachs & Co., Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma price target raised to $48 from $45 at Leerink
- NewAmsterdam price target raised to $40 from $31 at RBC Capital
- Verve Therapeutics has positive read from NewAmsterdam data, says Stifel
- Oracle reports mixed Q2, Gen Digital to acquire MoneyLion: Morning Buzz
- NewAmsterdam Pharma Unveils Promising Phase 3 Trial Results